Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2025-04-04 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2025-04-04 English
Mesoblast Cell Therapy Products Not Subject to U.S. Tariffs 2 pages 201.1KB
Regulatory Filings Classification · 95% confidence The document is a press release from Mesoblast providing an update on the tariff status of its allogeneic cell therapy products in relation to U.S. government tariffs. It includes company background, product information, intellectual property details, manufacturing overview, and forward-looking statements. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is informational and promotional in nature, typical of a corporate press release or announcement rather than a formal financial or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings that require substantive financial data or regulatory content. Given the content and length (7,363 characters), it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit any other specific category.
2025-04-03 English
6-K
Regulatory Filings
2025-04-03 English
Meeting Requested with FDA on Revascor Accelerated Approval 2 pages 200.1KB
Regulatory Filings Classification · 95% confidence The document is a press release from Mesoblast announcing a request for a Type B meeting with the FDA to discuss the accelerated approval pathway for their product Revascor in ischemic heart failure. It provides background on the company, the product, and regulatory context but does not contain any financial data, earnings, or detailed report content. It is an update on regulatory and development progress rather than a financial report or formal regulatory filing. The document is longer than 5,000 characters but is clearly an announcement of a regulatory meeting request and update, not a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-02 English
6-K
Regulatory Filings
2025-03-31 English
First Children To Begin Treatment, Medicaid Covers Ryoncil 2 pages 202.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that the first three children have commenced treatment with Ryoncil, and that the U.S. Centers for Medicare and Medicaid Services (CMS) has mandated coverage for Ryoncil under Medicaid. It discusses the commercial and regulatory achievement of the company Mesoblast, provides background on the company and its products, and includes forward-looking statements. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about a commercial and regulatory milestone rather than a financial report or regulatory filing. Therefore, it fits best into the category of a general regulatory announcement or corporate news release that does not fit into more specific categories. According to the classification rules, such documents are best classified as Regulatory Filings (RNS).
2025-03-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.